450 Participants Needed

Veteran-Centered Care for Advanced Liver Disease

(Vet-CALD Trial)

Recruiting at 4 trial locations
DL
FK
Overseen ByFasiha Kanwal, MD MSHS
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: VA Office of Research and Development
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment I-VCALD, Vet-CALD, Veteran-Centered Care for Advanced Liver Disease?

Research suggests that integrated care models, like the one used in the Veteran-Centered Care for Advanced Liver Disease, can improve outcomes by aligning treatments with patient priorities and reducing unplanned hospital visits, as seen in a nurse-led clinic for liver cirrhosis.12345

How is the Veteran-Centered Care treatment for advanced liver disease different from other treatments?

This treatment is unique because it focuses on integrating early supportive and palliative care with curative treatments, allowing patients, caregivers, and clinicians to collaboratively identify care that aligns with the patient's priorities, which is not commonly emphasized in standard treatments for advanced liver disease.24678

What is the purpose of this trial?

Advanced liver disease is a serious illness that disproportionately affects Veterans, many of whom hope for curative liver transplantation. However, too few receive a transplant and most continue to suffer from increasing symptoms and hospitalizations. The proposed project uses a whole person, Veteran-centered approach that identifies Veterans with advanced liver disease using a population-based health management system and integrates curative and early supportive care using a telemedicine-based nurse care counselor to (1) discuss patient's understanding of illness severity and prognosis, (2) identify priorities and care preferences and (3) align curative and supportive care options to achieve patient priorities. Study outcomes include changes in (1) rates of consideration for liver transplantation, and (2) completion of serious illness discussions. Findings will inform adaptations to the intervention and facilitators for its dissemination.

Research Team

FK

Fasiha Kanwal, MD MSHS

Principal Investigator

Michael E. DeBakey VA Medical Center, Houston, TX

Eligibility Criteria

This trial is for Veterans aged 18-80 with advanced liver disease who have been in care at a recruiting site for over a year. They must speak English, have phone or computer access, and be able to consent. Those already on the transplant list or with limited life expectancy are excluded.

Inclusion Criteria

I have advanced liver disease with recent complications or a MELD-Na score over 15.
You must be a Veteran to qualify.
You have been under the care of one of the participating sites for at least 12 consecutive months, including two or more visits to your primary healthcare provider.

Exclusion Criteria

I have been diagnosed with uncontrolled mental health issues or schizophrenia.
Non-Veteran patients
Patients with very limited life expectancy (advanced cancer, acute-on-chronic liver failure, and hospice patients)
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive the Vet-CALD intervention, which includes 5 monthly 60-minute care counselor sessions over 6 months via telehealth

6 months
5 visits (virtual)

Follow-up

Participants are monitored for changes in consideration for liver transplantation and goals of care conversations

12 months

Treatment Details

Interventions

  • I-VCALD
Trial Overview The I-VCALD study tests a telemedicine-based approach where nurses help Veterans understand their illness, identify care preferences, and align treatment options. It aims to increase rates of liver transplant consideration and serious illness discussions.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Arm 1: Vet-CALD InterventionExperimental Treatment1 Intervention
Vet-CALD Participants will receive the standard of care from their usual VA healthcare provider, plus they will participate in 5 monthly 60-minute care counselor sessions over a period of 6 months via VA Video Connect (VVC) or by telephone. The purpose of care counselor visits is to assess and cultivate the patient's understanding of their illness and identify personal healthcare goals. The counselor will be part of a centralized research care team (hepatologist and supportive care physician) and will work with each patient's usual VA care providers to help tailor treatment plans and education to better align with each patient's understanding of their disease prognosis and their healthcare goals and priorities.
Group II: Arm 2: Usual CareActive Control1 Intervention
Usual Care Participants will receive the standard of care from their usual VA healthcare provider. The care counselor will not contact the usual care condition participants.

Find a Clinic Near You

Who Is Running the Clinical Trial?

VA Office of Research and Development

Lead Sponsor

Trials
1,691
Recruited
3,759,000+

Findings from Research

The nurse-led Care Coordination of Liver Disease (CCoLD) clinic significantly reduced unplanned liver-related readmissions to 2.08% compared to 12.2% in the standard care group, indicating improved patient outcomes.
Mortality rates at 30 days were also lower in the CCoLD cohort (0%) compared to the control group (7.3%), demonstrating the efficacy of integrated care in managing patients with advanced chronic liver disease.
A novel, nurse-led 'one stop' clinic for patients with liver cirrhosis results in fewer liver-related unplanned readmissions and improved survival.Kalo, E., Baig, A., Gregg, E., et al.[2023]
Implementing a hepatologist-led advance care planning intervention significantly increased advance directive (AD) completion rates from 8% to 31% and goals of care discussion (GCD) rates from 0% to 51% among 62 patients with decompensated cirrhosis.
The intervention highlighted that women and nonmarried adults showed greater improvements in AD completion, while providers identified time constraints as a major barrier to advance care planning discussions.
Improving Advance Care Planning in Outpatients With Decompensated Cirrhosis: A Pilot Study.Patel, A., Kogekar, N., Agarwal, R., et al.[2021]
Over 70% of Medicare beneficiaries with advanced liver disease died during the study period from 2005 to 2009, highlighting the high mortality associated with this condition.
Key predictors of mortality included admission to the intensive care unit (ICU) and a higher Charlson Comorbidity Index, while ICU admission and thoracentesis procedures were linked to increased hospital length of stay and costs, indicating the severity of illness.
Resource utilization and survival among Medicare patients with advanced liver disease.Otgonsuren, M., Henry, L., Hunt, S., et al.[2021]

References

A novel, nurse-led 'one stop' clinic for patients with liver cirrhosis results in fewer liver-related unplanned readmissions and improved survival. [2023]
Improving Advance Care Planning in Outpatients With Decompensated Cirrhosis: A Pilot Study. [2021]
Resource utilization and survival among Medicare patients with advanced liver disease. [2021]
Integrated Model for Patient-Centered Advanced Liver Disease Care. [2022]
Core implementation strategies for improving cirrhosis care in the Veterans Health Administration. [2023]
Access to Comprehensive Services for Advanced Liver Disease in the Veterans Health Administration. [2022]
Comprehensive Care of Patients with Chronic Liver Disease. [2015]
Advance care planning (ACP) for specialists managing cirrhosis: A focus on patient-centered care. [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity